Cerus Q2 2026 revenue with IFC growth and updated guidance
Cerus reported total revenue of $63.3 million for Q2 2026 and raised its full-year 2026 product revenue guidance range to $229 to $231 million, driven by strong performance of its INTERCEPT Fibrinogen Complex franchise.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day